CompletedPhase 2

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

United States250 participantsStarted 2003-11

Plain-language summary

An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * High-density lipoprotein cholesterol less than or equal to 45 mg/dL. * Triglycerides greater than or equal to 120 mg/dL and less than or equal to 500 mg/dL. * Women must be surgically sterile or postmenopausal. Exclusion criteria: * Heart disease * Diabetes

What they're measuring

change from baseline in fasting plasma HDLc concentration at the end of eight weeks of double blind treatment

Timeframe: 8 weeks

Trial details

NCT IDNCT00169559

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-04

View on ClinicalTrials.gov More Dyslipidaemias trials